Tenaya Therapeutics' TN-301 Data Sparks 47.7% Rally Amid Reduced Losses and Alnylam Deal

Tenaya Therapeutics' share price rose 47.7% after positive TN-301 DMD data and a new research collaboration with Alnylam Pharmaceuticals. TN-301 showed stronger preclinical muscle and cardiac effects without similar side-effect signals compared to the approved pan-HDAC inhibitor givinostat. The company's investment narrative has shifted with the fresh data adding a new pillar to the story, widening Tenaya's optionality in rare muscle disease and broader cardiovascular indications.